Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOUNTAINEER-02: Tucatinib in HER2+ Gastric/GEJ Cancer
NCT04499924Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Mar 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of tucatinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Seagen Inc.. Started Mar 2021; status: completed.
02
Drugs
tucatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04499924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499924.